Di Nardo and colleagues’ data on VEN in combination with HMAs in the treatment- naïve elderly AML demonstrated that this combination was effective in most cytogenetic subgroups, including in patients harboring high-risk molecular features, IDH1/2 lesions, and secondary AML [80,84]. The gene discussed is IDH1; the disease is acute myeloid leukemia.